Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride
monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the ...
Nilotinib may cause QT prolongation (an irregular heart rhythm that can lead to
fainting, loss of consciousness, seizures, or sudden death). Tell your doctor if you
Jul 3, 2013 ... Information from the FDA about the approval of nilotinib and the clinical trials that
led to the approval.
This page contains brief information about nilotinib and a collection of links to
more information about the use of this drug, research results, and ongoing
TASIGNA<sup>®</sup> (nilotinib) is indicated for the treatment of newly diagnosed adult
patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+
Nilotinib | C28H22F3N7O | CID 644241 - structure, chemical names, physical
and chemical properties, classification, patents, literature, biological activities, ...
Jan 2, 2015 ... Read about the cancer treatment drug nilotinib, otherwise known as Tasigna,
including what it is, how it works and possible side effects.
Nov 30, 2015 ... Learn about Tasigna Capsules (Nilotinib Capsules) may treat, uses, dosage, side
effects, drug interactions, warnings, patient labeling, reviews, ...
BACKGROUND: Nilotinib, a second-generation tyrosine kinase inhibitor (TKI)
formerly known as AMN107, was approved by the US Food and Drug ...
Semin Oncol. 2011 Apr;38 Suppl 1:S3-9. doi: 10.1053/j.seminoncol.2011.01.016.
Nilotinib: a novel, selective tyrosine kinase inhibitor. Blay JY(1), von Mehren M.